SPEC vs. TSTL, BVC, AKR, CNSL, ODX, CTEC, AMS, ARIX, ANCR, and CIR
Should you be buying INSPECS Group stock or one of its competitors? The main competitors of INSPECS Group include Tristel (TSTL), BATM Advanced Communications (BVC), Akers Biosciences (AKR), Cambridge Nutritional Sciences (CNSL), Omega Diagnostics Group (ODX), ConvaTec Group (CTEC), Advanced Medical Solutions Group (AMS), Arix Bioscience (ARIX), Animalcare Group (ANCR), and Circassia Group (CIR). These companies are all part of the "medical" sector.
INSPECS Group vs. Its Competitors
Tristel (LON:TSTL) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.
In the previous week, Tristel had 6 more articles in the media than INSPECS Group. MarketBeat recorded 6 mentions for Tristel and 0 mentions for INSPECS Group. Tristel's average media sentiment score of 0.98 beat INSPECS Group's score of 0.00 indicating that Tristel is being referred to more favorably in the media.
Tristel has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, INSPECS Group has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500.
Tristel has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.
37.8% of Tristel shares are owned by institutional investors. Comparatively, 27.1% of INSPECS Group shares are owned by institutional investors. 21.1% of Tristel shares are owned by insiders. Comparatively, 20.6% of INSPECS Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Tristel has a net margin of 15.47% compared to INSPECS Group's net margin of -2.10%. Tristel's return on equity of 20.43% beat INSPECS Group's return on equity.
Tristel currently has a consensus target price of GBX 400, indicating a potential upside of 13.96%. INSPECS Group has a consensus target price of GBX 60, indicating a potential upside of 42.86%. Given INSPECS Group's stronger consensus rating and higher probable upside, analysts clearly believe INSPECS Group is more favorable than Tristel.
Summary
Tristel beats INSPECS Group on 11 of the 16 factors compared between the two stocks.
Get INSPECS Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SPEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
INSPECS Group Competitors List
Related Companies and Tools
This page (LON:SPEC) was last updated on 10/19/2025 by MarketBeat.com Staff
